Taiho Pharmaceutical Co, Ltd. announces that it and Astex Pharmaceuticals (UK), both Otsuka group companies, have granted an exclusive licence under their joint, small-molecule drug discovery programme targeting SHP2, to Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada through a subsidiary.
Astex Pharmaceuticals
Astex Pharmaceuticals™ is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.
Telephone: +44 (0)1223 226 200
Address :
436 Cambridge Science Park Milton Road Cambridge
Post Code: CB4 0QA
Country: United Kingdom
Website: http://www.astx.com
Membership Type: Corporate 51+
Innovative Discovery
Enhanced Opportunities
Astex Pharmaceuticals™ is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.
- Fiscal strength with significant cash, ongoing revenues and potential milestone payments
- Productive partnerships with top-tier pharmaceutical companies
- Rich product portfolio with multiple drugs in clinical development
- Visionary leadership backed by a world-class management team
Oncology Focused
We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Our primary areas of focus are oncology and hematology.
Financially Strong
We are a publicly traded pharmaceutical company with strong cash reserves and royalty revenues from the sales of our product DACOGEN®. In addition, our partnerships could deliver future product milestones plus royalties.
There are no Products & Services to display
Astex Pharmaceuticals welcomes positive, new data showing breast cancer drug, Kisqali® (ribociclib), cuts risk of death by up to a third when given with hormone therapy.
10-06-2019
Astex Pharmaceuticals and Otsuka announce results of the phase 3 ASCERTAIN study of the novel oral cedazuridine and decitabine fixed-dose combination (ASTX727) in patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML).
07-06-2019
Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that Harren Jhoti PhD, co-founder of Astex and President and CEO of Astex Pharmaceuticals (UK) has been elected a Fellow of the Royal Society in recognition of his outstanding contribution to...
09-05-2018
Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced that its pharmaceutical collaborator, Janssen Pharmaceutica NV has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer.
16-03-2018
The Dementia Consortium, a unique charity-private partnership, today announced Astex Pharmaceuticals as a new member.
12-10-2015
Cancer Research UK's Drug Development Office (DDO) has announced that Astex Pharmaceuticals will join its Experimental Cancer Medicine Centre (ECMC) Combinations Alliance with an aim to develop new cancer treatments.
16-05-2014
There are no events to display
There are no jobs to display
No Blog articles found
